138 related articles for article (PubMed ID: 22086405)
21. NCT01110291: induction of CYP3A activity and lowered exposure to docetaxel in patients with primary breast cancer.
Hilli J; Sailas L; Jyrkkiö S; Pyrhönen S; Laine K
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1353-62. PubMed ID: 20798939
[TBL] [Abstract][Full Text] [Related]
22. Prophylactic management for taxane-induced nail toxicity: A systematic review and meta-analysis.
Huang KL; Lin KY; Huang TW; Loh EW; Hua YM; Su HC; Tam KW
Eur J Cancer Care (Engl); 2019 Sep; 28(5):e13118. PubMed ID: 31184794
[TBL] [Abstract][Full Text] [Related]
23. Docetaxel-induced palmoplantar erythrodysesthesia syndrome and long-lasting multiple nail changes.
Akoglu G
Indian J Pharmacol; 2014; 46(2):225-7. PubMed ID: 24741199
[TBL] [Abstract][Full Text] [Related]
24. A randomized feasibility study of docetaxel versus vinorelbine in advanced breast cancer.
Palmieri C; Alifrangis C; Shipway D; Tat T; Watson V; Mackie D; Emson M; Coombes RC
Oncologist; 2012; 17(11):1429-e47. PubMed ID: 23002126
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial simulations for dosage optimization of docetaxel in patients with liver dysfunction, based on a log-binominal regression for febrile neutropenia.
Ozawa K; Minami H; Sato H
Yakugaku Zasshi; 2009 Jun; 129(6):749-57. PubMed ID: 19483418
[TBL] [Abstract][Full Text] [Related]
26. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer.
Eckhoff L; Knoop AS; Jensen MB; Ejlertsen B; Ewertz M
Breast Cancer Res Treat; 2013 Nov; 142(1):109-18. PubMed ID: 24132874
[TBL] [Abstract][Full Text] [Related]
27. Pilot study to assess toxicity and pharmacokinetics of docetaxel in patients with metastatic breast cancer and impaired liver function secondary to hepatic metastases.
Eckmann K; Michaud LB; Rivera E; Madden TL; Esparza-Guerra L; Kawedia J; Booser DJ; Green MC; Hortobagyi GN; Valero V
J Oncol Pharm Pract; 2014 Apr; 20(2):120-9. PubMed ID: 23676510
[TBL] [Abstract][Full Text] [Related]
28. Nail changes secondary to docetaxel (Taxotere).
Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
[TBL] [Abstract][Full Text] [Related]
29. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
31. Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study.
Freyer G; Hennebert P; Awada A; Gil T; Kerger J; Selleslags J; Brassinne C; Piccart M; de Valeriola D
Clin Cancer Res; 2002 Jan; 8(1):95-102. PubMed ID: 11801544
[TBL] [Abstract][Full Text] [Related]
32. Protracted administration of weekly docetaxel in metastatic breast cancer.
Kuroi K; Bando H; Saji S; Toi M
Oncol Rep; 2003; 10(5):1479-84. PubMed ID: 12883727
[TBL] [Abstract][Full Text] [Related]
33. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
Cho EK; Park JY; Lee KH; Song HS; Min YJ; Kim YH; Kang JH
Cancer Chemother Pharmacol; 2014 Jan; 73(1):9-16. PubMed ID: 24337589
[TBL] [Abstract][Full Text] [Related]
34. Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study.
Sparano JA; Makhson AN; Semiglazov VF; Tjulandin SA; Balashova OI; Bondarenko IN; Bogdanova NV; Manikhas GM; Oliynychenko GP; Chatikhine VA; Zhuang SH; Xiu L; Yuan Z; Rackoff WR
J Clin Oncol; 2009 Sep; 27(27):4522-9. PubMed ID: 19687336
[TBL] [Abstract][Full Text] [Related]
35. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
36. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients?
Minami H; Ohe Y; Niho S; Goto K; Ohmatsu H; Kubota K; Kakinuma R; Nishiwaki Y; Nokihara H; Sekine I; Saijo N; Hanada K; Ogata H
J Clin Oncol; 2004 Jul; 22(14):2901-8. PubMed ID: 15254059
[TBL] [Abstract][Full Text] [Related]
37. Comparison of an AC-taxane versus AC-free regimen and paclitaxel versus docetaxel in patients with lymph node-positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study.
Watanabe T; Kuranami M; Inoue K; Masuda N; Aogi K; Ohno S; Iwata H; Mukai H; Uemura Y; Ohashi Y
Cancer; 2017 Mar; 123(5):759-768. PubMed ID: 28081304
[TBL] [Abstract][Full Text] [Related]
38. Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Ben Nasr S; Zribi A; Ben Hassen M; Doghri Y; Ben Abdallah I; Trigui E; Fendri S; Ayari J; Balti M; Haddaoui A
Bull Cancer; 2021 Mar; 108(3):266-271. PubMed ID: 33423777
[TBL] [Abstract][Full Text] [Related]
39. [Onycholysis due to docetaxel in breast cancer treatment].
Grasland A; Grandjean M; Rist S; Bosquet A; Vinceneux P
Rev Med Interne; 2005 May; 26(5):427-8. PubMed ID: 15893036
[No Abstract] [Full Text] [Related]
40. Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer.
Stemmler HJ; Harbeck N; Gröll de Rivera I; Vehling Kaiser U; Rauthe G; Abenhardt W; Artmann A; Sommer H; Meerpohl HG; Kiechle M; Heinemann V
Oncology; 2010; 79(3-4):197-203. PubMed ID: 21358207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
